We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A California supplement maker is in hot water after being accused of making drug-like claims about its products and relying on improper production methods. Read More
Drugmarkers are reporting a 20 percent improvement in securing their supply chains compared with a year ago, according to findings from a new report. Read More
Two House members are asking two embattled drugmakers for information and documents related to some of their products ahead of a Jan. 26 hearing on prescription drug pricing. Read More
Botox maker Allergan shelled out $90 million upfront to acquire dermatology drugmaker Anterios in a deal that will provide access to a pipeline of neurotoxin therapies. Read More
Dr. Reddy’s Laboratories has adopted a unique strategy to bypass legal issues surrounding its generic version of Nexium: changing the color of its capsules. Read More
Participants in a Dec. 9, 2015, Senate hearing — which addressed drug price manipulation of generics in uncontested markets — said the best way to stem the practice is to speed competitors to market and consider using compounders. Read More
Tuesday brought another setback for MannKind's Afrezza, with the company announcing that Sanofi will stop selling the rapid-acting inhaled insulin effective April 4, thus terminating a licensing deal the companies reached in 2014. Read More